

1 ENGROSSED SENATE
2 BILL NO. 860

By: Weaver of the Senate

3 and

4 Kannady of the House

5
6 An Act relating to the Uniform Controlled Dangerous
7 Substances Act; amending 63 O.S. 2021, Section 2-204,
8 as last amended by Section 3, Chapter 308, O.S.L.
9 2024 (63 O.S. Supp. 2024, Section 2-204), which
relates to Schedule I substances; adding certain
substance to Schedule I; and providing an effective
date.

10

11

12

BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA:

13

SECTION 1. AMENDATORY 63 O.S. 2021, Section 2-204, as

14

last amended by Section 3, Chapter 308, O.S.L. 2024 (63 O.S. Supp.

15

2024, Section 2-204), is amended to read as follows:

16

Section 2-204. The controlled substances listed in this section

17

are included in Schedule I and include any material, compound,

18

mixture, or preparation that contains any quantity of the following

19

hallucinogenic substances, their salts, isomers, and salts of

20

isomers, unless specifically excepted, when the existence of these

21

salts, isomers, and salts of isomers is possible within the specific

22

chemical designation.

23

A. Any of the following opiates including their isomers,

24

esters, ethers, salts, and salts of isomers, esters, and ethers,

1 unless specifically excepted, when the existence of these isomers,
2 esters, ethers, and salts is possible within the specific chemical
3 designation:

- 4 1. Acetylmethadol;
- 5 2. Allylprodine;
- 6 3. Alphacetylmethadol;
- 7 4. Alphameprodine;
- 8 5. Alphamethadol;
- 9 6. Benzethidine;
- 10 7. Betacetylmethadol;
- 11 8. Betameprodine;
- 12 9. Betamethadol;
- 13 10. Betaprodine;
- 14 11. Clonitazene;
- 15 12. Dextromoramide;
- 16 13. Dextrorphan (except its methyl ether);
- 17 14. Diampromide;
- 18 15. Diethylthiambutene;
- 19 16. Dimenoxadol;
- 20 17. Dimepheptanol;
- 21 18. Dimethylthiambutene;
- 22 19. Dioxaphetyl butyrate;
- 23 20. Dipipanone;
- 24 21. Ethylmethylthiambutene;

- 1 22. Etonitazene;
- 2 23. Etoxeridine;
- 3 24. Furethidine;
- 4 25. Hydroxypethidine;
- 5 26. Isotonitazene;
- 6 27. Ketobemidone;
- 7 28. Levomoramide;
- 8 29. Levophenacylmorphane;
- 9 30. Metonitazene;
- 10 31. Morpheridine;
- 11 32. N-desethyl isotonitazene;
- 12 33. N-pyrrolidino protonitazene;
- 13 34. Noracymethadol;
- 14 35. Norlevorphanol;
- 15 36. Normethadone;
- 16 37. Norpipanone;
- 17 38. Phenadoxone;
- 18 39. Phenampromide;
- 19 40. Phenomorphan;
- 20 41. Phenoperidine;
- 21 42. Piritramide;
- 22 43. Proheptazine;
- 23 44. Properidine;
- 24 45. Protonitazene;

- 1 46. Racemoramide; or
- 2 47. Trimeperidine.
- 3 B. Any of the following opium derivatives, their salts,
- 4 isomers, and salts of isomers, unless specifically excepted, when
- 5 the existence of these salts, isomers, and salts of isomers is
- 6 possible within the specific chemical designation:
- 7 1. Acetorphine;
- 8 2. Acetyldihydrocodeine;
- 9 3. Benzylmorphine;
- 10 4. Codeine methylbromide;
- 11 5. Codeine-N-Oxide;
- 12 6. Cyprenorphine;
- 13 7. Desomorphine;
- 14 8. Dihydromorphine;
- 15 9. Etorphine;
- 16 10. Heroin;
- 17 11. Hydromorphinol;
- 18 12. Methyldesorphine;
- 19 13. Methylhydromorphine;
- 20 14. Morphine methylbromide;
- 21 15. Morphine methylsulfonate;
- 22 16. Morphine-N-Oxide;
- 23 17. Myrophine;
- 24 18. Nicocodeine;

- 1 19. Nicomorphine;
- 2 20. Normorphine;
- 3 21. Phoclodine;
- 4 22. Thebacon;
- 5 23. N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-acetamide
- 6 (Acetyl fentanyl);
- 7 24. N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-butenamide
- 8 (Crotonyl fentanyl);
- 9 25. N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-2-
- 10 furancarboxamide (Furanyl fentanyl);
- 11 26. N-phenyl-1-(2-phenylethyl)-4-piperidinamine (4-ANPP);
- 12 27. N-(1-phenethylpiperidin-4-yl)-N-
- 13 phenylcyclopropanecarboxamide (Cyclopropyl fentanyl); or
- 14 28. N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-butanamide
- 15 (Butyrl fentanyl).
- 16 C. Any material, compound, mixture, or preparation which
- 17 contains any quantity of the following hallucinogenic substances,
- 18 their salts, isomers, and salts of isomers, unless specifically
- 19 excepted, when the existence of these salts, isomers, and salts of
- 20 isomers is possible within the specific chemical designation:
- 21 1. Methcathinone;
- 22 2. 3, 4-methylenedioxy amphetamine;
- 23 3. 3, 4-methylenedioxy methamphetamine;
- 24 4. 5-methoxy-3, 4-methylenedioxy amphetamine;

- 1 5. 3, 4, 5-trimethoxy amphetamine;
- 2 6. Bufotenine;
- 3 7. Diethyltryptamine;
- 4 8. Dimethyltryptamine;
- 5 9. 4-methyl-2, 5-dimethoxyamphetamine;
- 6 10. Ibogaine;
- 7 11. Lysergic acid diethylamide;
- 8 12. Marijuana;
- 9 13. Mescaline;
- 10 14. N-benzylpiperazine;
- 11 15. N-ethyl-3-piperidyl benzilate;
- 12 16. N-methyl-3-piperidyl benzilate;
- 13 17. Psilocybin;
- 14 18. Psilocyn;
- 15 19. 2, 5 dimethoxyamphetamine;
- 16 20. 4 Bromo-2, 5-dimethoxyamphetamine;
- 17 21. 4 methoxyamphetamine;
- 18 22. Cyclohexamine;
- 19 23. Salvia Divinorum;
- 20 24. Salvinorin A;
- 21 25. Thiophene Analog of Phencyclidine. Also known as: 1-(1-(2-
- 22 thienyl) cyclohexyl) piperidine; 2-Thienyl Analog of Phencyclidine;
- 23 TCP, TCP;
- 24 26. Phencyclidine (PCP);

- 1 27. Pyrrolidine Analog for Phencyclidine. Also known as 1-(1-
- 2 Phenylcyclohexyl) - Pyrrolidine, PCPy, PHP;
- 3 28. 1-(3-trifluoromethylphenyl) piperazine;
- 4 29. Flunitrazepam;
- 5 30. B-hydroxy-amphetamine;
- 6 31. B-ketoamphetamine;
- 7 32. 2,5-dimethoxy-4-nitroamphetamine;
- 8 33. 2,5-dimethoxy-4-bromophenethylamine;
- 9 34. 2,5-dimethoxy-4-chlorophenethylamine;
- 10 35. 2,5-dimethoxy-4-iodoamphetamine;
- 11 36. 2,5-dimethoxy-4-iodophenethylamine;
- 12 37. 2,5-dimethoxy-4-methylphenethylamine;
- 13 38. 2,5-dimethoxy-4-ethylphenethylamine;
- 14 39. 2,5-dimethoxy-4-fluorophenethylamine;
- 15 40. 2,5-dimethoxy-4-nitrophenethylamine;
- 16 41. 2,5-dimethoxy-4-ethylthio-phenethylamine;
- 17 42. 2,5-dimethoxy-4-isopropylthio-phenethylamine;
- 18 43. 2,5-dimethoxy-4-propylthio-phenethylamine;
- 19 44. 2,5-dimethoxy-4-cyclopropylmethylthio-phenethylamine;
- 20 45. 2,5-dimethoxy-4-tert-butylthio-phenethylamine;
- 21 46. 2,5-dimethoxy-4-(2-fluoroethylthio)-phenethylamine;
- 22 47. 5-methoxy-N, N-dimethyltryptamine;
- 23 48. N-methyltryptamine;
- 24 49. A-ethyltryptamine;

- 1 50. A-methyltryptamine;
- 2 51. N, N-diethyltryptamine;
- 3 52. N, N-diisopropyltryptamine;
- 4 53. N, N-dipropyltryptamine;
- 5 54. 5-methoxy-a-methyltryptamine;
- 6 55. 4-hydroxy-N, N-diethyltryptamine;
- 7 56. 4-hydroxy-N, N-diisopropyltryptamine;
- 8 57. 5-methoxy-N, N-diisopropyltryptamine;
- 9 58. 4-hydroxy-N-isopropyl-N-methyltryptamine;
- 10 59. 3,4-Methylenedioxy-methcathinone (Methylone);
- 11 60. 3,4-Methylenedioxy-pyrovalerone (MDPV);
- 12 61. 3-Methylmethcathinone (Metaphedrone);
- 13 62. 4-Methylmethcathinone (Mephedrone);
- 14 63. 4-methoxymethcathinone;
- 15 64. 4-Fluoromethcathinone;
- 16 65. 3-Fluoromethcathinone;
- 17 66. 1-(8-bromobenzo 1,2-b;4,5-b' difuran-4-yl)-2-aminopropane;
- 18 67. 2,5-Dimethoxy-4-chloroamphetamine;
- 19 68. 4-Methylethcathinone;
- 20 69. Pyrovalerone;
- 21 70. N,N-diallyl-5-methoxytryptamine;
- 22 71. 3,4-Methylenedioxy-N-ethylcathinone (Ethylone);
- 23 72. B-keto-N-Methylbenzodioxolylbutanamine (Butylone);
- 24 73. B-keto-Methylbenzodioxolylpentanamine (Pentylone);

- 1 74. Alpha-Pyrrolidinopentiophenone;
- 2 75. 4-Fluoroamphetamine;
- 3 76. Pentedrone;
- 4 77. 4'-Methyl-a-pyrrolidinohexaphenone;
- 5 78. 2,5-dimethoxy-4-(n)-propylphenethylamine;
- 6 79. 2,5-dimethoxyphenethylamine;
- 7 80. 1,4-Dibenzylpiperazine;
- 8 81. N,N-Dimethylamphetamine;
- 9 82. 4-Fluoromethamphetamine;
- 10 83. 4-Chloro-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine
11 (25C-NBOMe);
- 12 84. 4-Iodo-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine
13 (25I-NBOMe);
- 14 85. 4-Bromo-2,5-dimethoxy-N-(2-methoxybenzy)phenethylamine
15 (25B-NBOMe);
- 16 86. 1-(4-Fluorophenyl)piperazine;
- 17 87. Methoxetamine;
- 18 88. 3,4-dichloro-N[2-dimethylamino)cyclohexyl]-N-
19 methylbenzamide;
- 20 89. N-ethyl hexadrone;
- 21 90. Isopropyl-U-47700;
- 22 91. Para-fluorobutyrl fentanyl;
- 23 92. Para-fluorofentanyl (pFF);
- 24 93. Fluoro isobutryrl fentanyl;

1 94. 3-Hydroxy Phencyclidine (PCP);

2 95. 3-methoxy Phencyclidine (PCP);

3 96. Flualprazolam; or

4 97. Flubromazolam.

5 D. Unless specifically excepted or unless listed in a different
6 schedule, any material, compound, mixture, or preparation which
7 contains any quantity of the following substances having stimulant
8 or depressant effect on the central nervous system:

9 1. Fenethylline;

10 2. Mecloqualone;

11 3. N-ethylamphetamine;

12 4. Methaqualone;

13 5. Gamma-Hydroxybutyric Acid, also known as GHB, gamma-
14 hydroxybutyrate, 4-hydroxybutyrate, 4-hydroxybutanoic acid, sodium
15 oxybate, and sodium oxybutyrate;

16 6. Gamma-Butyrolactone (GBL) as packaged, marketed,
17 manufactured, or promoted for human consumption, with the exception
18 of legitimate food additive and manufacturing purposes;

19 7. Gamma Hydroxyvalerate (GHV) as packaged, marketed, or
20 manufactured for human consumption, with the exception of legitimate
21 food additive and manufacturing purposes;

22 8. Gamma Valerolactone (GVL) as packaged, marketed, or
23 manufactured for human consumption, with the exception of legitimate
24 food additive and manufacturing purposes;

1 9. 1,4 Butanediol (1,4 BD or BDO) as packaged, marketed,
2 manufactured, or promoted for human consumption with the exception
3 of legitimate manufacturing purposes; or

4 10. N-ethylpentylone.

5 E. 1. The following industrial uses of Gamma-Butyrolactone,
6 Gamma Hydroxyvalerate, Gamma Valerolactone, or 1,4 Butanediol are
7 excluded from all schedules of controlled substances under this
8 title:

- 9 a. pesticides,
- 10 b. photochemical etching,
- 11 c. electrolytes of small batteries or capacitors,
- 12 d. viscosity modifiers in polyurethane,
- 13 e. surface etching of metal coated plastics,
- 14 f. organic paint disbursements for water soluble inks,
- 15 g. pH regulators in the dyeing of wool and polyamide
16 fibers,
- 17 h. foundry chemistry as a catalyst during curing,
- 18 i. curing agents in many coating systems based on
19 urethanes and amides,
- 20 j. additives and flavoring agents in food, confectionary,
21 and beverage products,
- 22 k. synthetic fiber and clothing production,
- 23 l. tetrahydrofuran production,
- 24 m. gamma butyrolactone production,

- n. polybutylene terephthalate resin production,
- o. polyester raw materials for polyurethane elastomers and foams,
- p. coating resin raw material, and
- q. as an intermediate in the manufacture of other chemicals and pharmaceuticals.

2. At the request of any person, the Director of the Oklahoma State Bureau of Narcotics and Dangerous Drugs Control may exempt any other product containing Gamma-Butyrolactone, Gamma Hydroxyvalerate, Gamma Valerolactone, or 1,4 Butanediol from being included as a Schedule I controlled substance if such product is labeled, marketed, manufactured, and distributed for legitimate industrial use in a manner that reduces or eliminates the likelihood of abuse.

3. In making a determination regarding an industrial product, the Director, after notice and hearing, shall consider the following:

- a. the history and current pattern of abuse,
- b. the name and labeling of the product,
- c. the intended manner of distribution, advertising, and promotion of the product, and
- d. other factors as may be relevant to and consistent with the public health and safety.

4. The hearing shall be held in accordance with the procedures of the Administrative Procedures Act.

1 F. Any material, compound, mixture, or preparation, whether
2 produced directly or indirectly from a substance of vegetable origin
3 or independently by means of chemical synthesis, or by a combination
4 of extraction and chemical synthesis, that contains any quantity of
5 the following substances, or that contains any of their salts,
6 isomers, and salts of isomers when the existence of these salts,
7 isomers, and salts of isomers is possible within the specific
8 chemical designation:

- 9 1. JWH-004;
- 10 2. JWH-007;
- 11 3. JWH-009;
- 12 4. JWH-015;
- 13 5. JWH-016;
- 14 6. JWH-018;
- 15 7. JWH-019;
- 16 8. JWH-020;
- 17 9. JWH-030;
- 18 10. JWH-046;
- 19 11. JWH-047;
- 20 12. JWH-048;
- 21 13. JWH-049;
- 22 14. JWH-050;
- 23 15. JWH-070;
- 24 16. JWH-071;

- 1 17. JWH-072;
- 2 18. JWH-073;
- 3 19. JWH-076;
- 4 20. JWH-079;
- 5 21. JWH-080;
- 6 22. JWH-081;
- 7 23. JWH-082;
- 8 24. JWH-094;
- 9 25. JWH-096;
- 10 26. JWH-098;
- 11 27. JWH-116;
- 12 28. JWH-120;
- 13 29. JWH-122;
- 14 30. JWH-145;
- 15 31. JWH-146;
- 16 32. JWH-147;
- 17 33. JWH-148;
- 18 34. JWH-149;
- 19 35. JWH-150;
- 20 36. JWH-156;
- 21 37. JWH-167;
- 22 38. JWH-175;
- 23 39. JWH-180;
- 24 40. JWH-181;

- 1 41. JWH-182;
- 2 42. JWH-184;
- 3 43. JWH-185;
- 4 44. JWH-189;
- 5 45. JWH-192;
- 6 46. JWH-193;
- 7 47. JWH-194;
- 8 48. JWH-195;
- 9 49. JWH-196;
- 10 50. JWH-197;
- 11 51. JWH-198;
- 12 52. JWH-199;
- 13 53. JWH-200;
- 14 54. JWH-201;
- 15 55. JWH-202;
- 16 56. JWH-203;
- 17 57. JWH-204;
- 18 58. JWH-205;
- 19 59. JWH-206;
- 20 60. JWH-207;
- 21 61. JWH-208;
- 22 62. JWH-209;
- 23 63. JWH-210;
- 24 64. JWH-211;

- 1 65. JWH-212;
- 2 66. JWH-213;
- 3 67. JWH-234;
- 4 68. JWH-235;
- 5 69. JWH-236;
- 6 70. JWH-237;
- 7 71. JWH-239;
- 8 72. JWH-240;
- 9 73. JWH-241;
- 10 74. JWH-242;
- 11 75. JWH-243;
- 12 76. JWH-244;
- 13 77. JWH-245;
- 14 78. JWH-246;
- 15 79. JWH-248;
- 16 80. JWH-249;
- 17 81. JWH-250;
- 18 82. JWH-251;
- 19 83. JWH-252;
- 20 84. JWH-253;
- 21 85. JWH-262;
- 22 86. JWH-292;
- 23 87. JWH-293;
- 24 88. JWH-302;

- 1 89. JWH-303;
- 2 90. JWH-304;
- 3 91. JWH-305;
- 4 92. JWH-306;
- 5 93. JWH-307;
- 6 94. JWH-308;
- 7 95. JWH-311;
- 8 96. JWH-312;
- 9 97. JWH-313;
- 10 98. JWH-314;
- 11 99. JWH-315;
- 12 100. JWH-316;
- 13 101. JWH-346;
- 14 102. JWH-348;
- 15 103. JWH-363;
- 16 104. JWH-364;
- 17 105. JWH-365;
- 18 106. JWH-367;
- 19 107. JWH-368;
- 20 108. JWH-369;
- 21 109. JWH-370;
- 22 110. JWH-371;
- 23 111. JWH-373;
- 24 112. JWH-386;

- 1 113. JWH-387;
- 2 114. JWH-392;
- 3 115. JWH-394;
- 4 116. JWH-395;
- 5 117. JWH-397;
- 6 118. JWH-398;
- 7 119. JWH-399;
- 8 120. JWH-400;
- 9 121. JWH-412;
- 10 122. JWH-413;
- 11 123. JWH-414;
- 12 124. JWH-415;
- 13 125. CP-55, 940;
- 14 126. CP-47, 497;
- 15 127. HU-210;
- 16 128. HU-211;
- 17 129. WIN-55, 212-2;
- 18 130. AM-2201;
- 19 131. AM-2233;
- 20 132. JWH-018 adamantyl-carboxamide;
- 21 133. AKB48;
- 22 134. JWH-122 N-(4-pentenyl) analog;
- 23 135. MAM2201;
- 24 136. URB597;

- 1 137. URB602;
- 2 138. URB754;
- 3 139. UR144;
- 4 140. XLR11;
- 5 141. A-796,260;
- 6 142. STS-135;
- 7 143. AB-FUBINACA;
- 8 144. AB-PINACA;
- 9 145. PB-22;
- 10 146. AKB48 N-5-Fluoropentyl;
- 11 147. AM1248;
- 12 148. FUB-PB-22;
- 13 149. ADB-FUBINACA;
- 14 150. BB-22;
- 15 151. 5-Fluoro PB-22; or
- 16 152. 5-Fluoro AKB-48.

17 G. In addition to those substances listed in subsection F of
18 this section, unless specifically excepted or unless listed in
19 another schedule, any material, compound, mixture, or preparation
20 which contains any quantity of a synthetic cannabinoid found to be
21 in any of the following chemical groups:

- 22 1. Naphthoylindoles: any compound containing a 3-(1-
23 naphthoyl)indole structure with or without substitution at the
24 nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl,

1 alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-
2 (N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-
3 2-pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl,
4 (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or
5 halophenyl group, whether or not further substituted on the indole
6 ring to any extent, and whether or not substituted on the naphthyl
7 ring to any extent. Naphthoylindoles include, but are not limited
8 to:

- 9 a. 1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-
10 200),
- 11 b. 1-(5-fluoropentyl)-3-(1-naphthoyl)indole (AM2201),
- 12 c. 1-pentyl-3-(1-naphthoyl)indole (JWH-018),
- 13 d. 1-butyl-3-(1-naphthoyl)indole (JWH-073),
- 14 e. 1-pentyl-3-(4-methoxy-1-naphthoyl)indole (JWH-081),
- 15 f. 1-propyl-2-methyl-3-(1-naphthoyl)indole (JWH-015),
- 16 g. 1-hexyl-3-(1-naphthoyl)indole (JWH-019),
- 17 h. 1-pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122),
- 18 i. 1-pentyl-3-(4-ethyl-1-naphthoyl)indole (JWH-210),
- 19 j. 1-pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-398),
- 20 k. 1-pentyl-2-methyl-3-(1-naphthoyl)indole (JWH-007),
- 21 l. 1-pentyl-3-(7-methoxy-1-naphthoyl)indole (JWH-164),
- 22 m. 1-pentyl-2-methyl-3-(4-methoxy-1-naphthoyl)indole
23 (JWH-098),
- 24 n. 1-pentyl-3-(4-fluoro-1-naphthoyl)indole (JWH-412),

- 1 o. 1-[1-(N-methyl-2-piperidinyl)methyl]-3-(1-
2 naphthoyl)indole (AM-1220),
3 p. 1-(5-fluoropentyl)-3-(4-methyl-1-naphthoyl)indole
4 (MAM-2201), or
5 q. 1-(4-cyanobutyl)-3-(1-naphthoyl)indole (AM-2232);

6 2. Naphthylmethylindoles: any compound containing a 1H-indol-
7 3-yl-(1-naphthyl)methane structure with or without substitution at
8 the nitrogen atom of the indole ring by an alkyl, haloalkyl,
9 cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl,
10 halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-
11 morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-
12 morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl,
13 phenyl, or halophenyl group, whether or not further substituted on
14 the indole ring to any extent, and whether or not substituted on the
15 naphthyl ring to any extent. Naphthylmethylindoles include, but are
16 not limited to, (1-pentylindol-3-yl)(1-naphthyl)methane (JWH-175);

17 3. Naphthoylpyrroles: any compound containing a 3-(1-
18 naphthoyl)pyrrole structure with or without substitution at the
19 nitrogen atom of the pyrrole ring by an alkyl, haloalkyl,
20 cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl,
21 halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-
22 morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-
23 morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl,
24 phenyl, or halophenyl group, whether or not further substituted on

1 the pyrrole ring to any extent, and whether or not substituted on
2 the naphthyl group to any extent. Naphthoylpyrroles include, but
3 are not limited to:

- 4 a. 1-hexyl-2-phenyl-4-(1-naphthoyl)pyrrole (JWH-147),
- 5 b. 1-pentyl-5-(2-methylphenyl)-3-(1-naphthoyl)pyrrole
6 (JWH-370),
- 7 c. 1-pentyl-3-(1-naphthoyl)pyrrole (JWH-030), or
- 8 d. 1-hexyl-5-phenyl-3-(1-naphthoyl)pyrrole (JWH-147);

9 4. Naphthylideneindenes: any compound containing a 1-(1-
10 naphthylmethylene)indene structure with or without substitution at
11 the 3-position of the indene ring by an alkyl, haloalkyl,
12 cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl,
13 halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-
14 morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-
15 morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl,
16 phenyl, or halophenyl group, whether or not further substituted on
17 the indene group to any extent, and whether or not substituted on
18 the naphthyl group to any extent. Naphthylmethylindenes include,
19 but are not limited to, (1-[(3-pentyl)-1H-inden-1-
20 ylidene)methyl]naphthalene (JWH-176);

21 5. Phenylacetylindoles: any compound containing a 3-
22 phenylacetylindole structure with or without substitution at the
23 nitrogen atom of the indole ring by alkyl, haloalkyl, cyanoalkyl,
24 alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-

1 (N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-
2 2-pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl,
3 (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or
4 halophenyl group, whether or not further substituted on the indole
5 ring to any extent, and whether or not substituted on the phenyl
6 ring to any extent. Phenylacetylindoles include, but are not
7 limited to:

- 8 a. 1-pentyl-3-(2-methoxyphenylacetyl)indole (JWH-250),
- 9 b. 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole
10 (RCS-8),
- 11 c. 1-pentyl-3-(2-chlorophenylacetyl)indole (JWH-203),
- 12 d. 1-pentyl-3-(2-methylphenylacetyl)indole (JWH-251),
- 13 e. 1-pentyl-3-(4-methoxyphenylacetyl)indole (JWH-201), or
- 14 f. 1-pentyl-3-(3-methoxyphenylacetyl)indole (JWH-302);

15 6. Cyclohexylphenols: any compound containing a 2-(3-
16 hydroxycyclohexyl)phenol structure with or without substitution at
17 the 5-position of the phenolic ring by an alkyl, haloalkyl,
18 cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl,
19 halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-
20 morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-
21 morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl,
22 phenyl, or halophenyl group, and whether or not further substituted
23 on the cyclohexyl ring to any extent. Cyclohexylphenols include,
24 but are not limited to:

- 1 a. 5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-
2 hydroxycyclohexyl]-phenol (CP-47,497),
3 b. 5-(1,1-dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-
4 phenol (cannabicyclohexanol; CP-47,497 C8 homologue),
5 or
6 c. 5-(1,1-dimethylheptyl)-2-[(1R,2R)-5-hydroxy-2-(3-
7 hydroxypropyl)cyclohexyl]-phenol (CP 55, 940);

8 7. Benzoylindoles: any compound containing a 3-(benzoyl)indole
9 structure with or without substitution at the nitrogen atom of the
10 indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl,
11 cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl-
12 2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-
13 pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl,
14 (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or
15 halophenyl group, whether or not further substituted on the indole
16 ring to any extent, and whether or not substituted on the phenyl
17 group to any extent. Benzoylindoles include, but are not limited
18 to:

- 19 a. 1-pentyl-3-(4-methoxybenzoyl)indole (RCS-4),
20 b. 1-[2-(4-morpholinyl)ethyl]-2-methyl-3-(4-
21 methoxybenzoyl)indole (Pravadoline or WIN 48, 098),
22 c. 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole (AM-694),
23 d. 1-pentyl-3-(2-iodobenzoyl)indole (AM-679), or
24

1 e. 1-[1-(N-methyl-2-piperidinyl)methyl]-3-(2-
2 iodobenzoyl)indole (AM-2233);

3 8. Cyclopropoylindoles: Any compound containing a 3-
4 (cyclopropoyl)indole structure with substitution at the nitrogen
5 atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl,
6 cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl-
7 2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-
8 pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl,
9 (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or
10 halophenyl group, whether or not further substituted in the indole
11 ring to any extent, and whether or not substituted in the
12 cyclopropoyl ring to any extent. Cyclopropoylindoles include, but
13 are not limited to:

14 a. 1-pentyl-3-(2,2,3,3-tetramethylcyclopropoyl)indole
15 (UR-144),

16 b. 1-(5-chloropentyl)-3-(2,2,3,3-
17 tetramethylcyclopropoyl)indole (5Cl-UR-144), or

18 c. 1-(5-fluoropentyl)-3-(2,2,3,3-
19 tetramethylcyclopropoyl)indole (XLR11);

20 9. Indole Amides: Any compound containing a 1H-Indole-3-
21 carboxamide structure with or without substitution at the nitrogen
22 atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl,
23 cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl-
24 2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-

1 pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl,
2 (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or
3 halophenyl group, whether or not substituted at the carboxamide
4 group by an adamantyl, naphthyl, phenyl, benzyl, quinolinyl,
5 cycloalkyl, 1-amino-3-methyl-1-oxobutan-2-yl, 1-amino-3,3-dimethyl-
6 1-oxobutan-2-yl, 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-methoxy-3,3-
7 dimethyl-1-oxobutan-2-yl or pyrrole group, and whether or not
8 further substituted in the indole, adamantyl, naphthyl, phenyl,
9 pyrrole, quinolinyl, or cycloalkyl rings to any extent. Indole
10 Amides include, but are not limited to:

- 11 a. N-(1-adamantyl)-1-pentyl-1H-indole-3-carboxamide
12 (2NE1),
- 13 b. N-(1-adamantyl)-1-(5-fluoropentyl-1H-indole-3-
14 carboxamide (STS-135),
- 15 c. N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-
16 indole-3-carboxamide (ADBICA),
- 17 d. N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(5-
18 fluoropentyl)-1H-indole-3-carboxamide (5F-ADBICA),
- 19 e. N-(naphthalen-1-yl)-1-pentyl-1H-indole-3-carboxamide
20 (NNE1),
- 21 f. 1-(5-fluoropentyl)-N-(naphthalene-1-yl)-1H-indole-3-
22 carboxamide (5F-NNE1),
- 23 g. N-benzyl-1-pentyl-1H-indole-3-carboxamide (SDB-006),
24 or

1 h. N-benzyl-1-(5-fluoropentyl)-1H-indole-3-carboxamide
2 (5F-SDB-006);

3 10. Indole Esters: Any compound containing a 1H-Indole-3-
4 carboxylate structure with or without substitution at the nitrogen
5 atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl,
6 cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl-
7 2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-
8 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl,
9 (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or
10 halophenyl group, whether or not substituted at the carboxylate
11 group by an adamantyl, naphthyl, phenyl, benzyl, quinolinyl,
12 cycloalkyl, 1-amino-3-methyl-1-oxobutan-2-yl, 1-amino-3,3-dimethyl-
13 1-oxobutan-2-yl, 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-methoxy-3,3-
14 dimethyl-1-oxobutan-2-yl or pyrrole group, and whether or not
15 further substituted in the indole, adamantyl, naphthyl, phenyl,
16 pyrrole, quinolinyl, or cycloalkyl rings to any extent. Indole
17 Esters include, but are not limited to:

18 a. quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate (PB-
19 22),

20 b. quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-
21 carboxylate (5F-PB-22),

22 c. quinolin-8-yl 1-(cyclohexylmethyl)-1H-indole-3-
23 carboxylate (BB-22),
24

- 1 d. naphthalen-1-yl 1-(4-fluorobenzyl)-1H-indole-3-
2 carboxylate (FDU-PB-22), or
3 e. naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-
4 carboxylate (NM2201);

5 11. Adamantanoylindoles: Any compound containing an
6 adamantanyl-(1H-indol-3-yl)methanone structure with or without
7 substitution at the nitrogen atom of the indole ring by an alkyl,
8 haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
9 benzyl, halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-
10 morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-
11 morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl,
12 phenyl, or halophenyl group, whether or not further substituted in
13 the indole ring to any extent, and whether or not substituted in the
14 adamantyl ring to any extent. Adamantanoylindoles include, but are
15 not limited to:

- 16 a. adamantan-1-yl[1-[(1-methyl-2-piperidinyl)methyl]-1H-
17 indol-3-yl]methanone (AM1248), or
18 b. adamantan-1-yl-(1-pentyl-1H-indol-3-yl)methanone (AB-
19 001);

20 12. Carbazole Ketone: Any compound containing (9H-carbazole-3-
21 yl) methanone structure with or without substitution at the nitrogen
22 atom of the carbazole ring by an alkyl, haloalkyl, cyanoalkyl,
23 alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-
24 (N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-

1 2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl,
2 (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or
3 halophenyl group, with substitution at the carbon of the methanone
4 group by an adamantyl, naphthyl, phenyl, benzyl, quinolinyl,
5 cycloalkyl, 1-amino-3-methyl-1-oxobutan-2-yl, 1-amino-3,3-dimethyl-
6 1-oxobutan-2-yl, 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-methoxy-3,3-
7 dimethyl-1-oxobutan-2-yl or pyrrole group, and whether or not
8 further substituted at the carbazole, adamantyl, naphthyl, phenyl,
9 pyrrole, quinolinyl, or cycloalkyl rings to any extent. Carbazole
10 Ketones include, but are not limited to, naphthalen-1-yl(9-pentyl-
11 9H-carbazol-3-yl)methanone (EG-018);

12 13. Benzimidazole Ketone: Any compound containing
13 (benzimidazole-2-yl) methanone structure with or without
14 substitution at either nitrogen atom of the benzimidazole ring by an
15 alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl,
16 cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl-2-
17 piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-
18 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl,
19 (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or
20 halophenyl group, with substitution at the carbon of the methanone
21 group by an adamantyl, naphthyl, phenyl, benzyl, quinolinyl,
22 cycloalkyl, 1-amino-3-methyl-1-oxobutan-2-yl, 1-amino-3,3-dimethyl-
23 1-oxobutan-2-yl, 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-methoxy-3,3-
24 dimethyl-1-oxobutan-2-yl or pyrrole group, and whether or not

1 further substituted in the benzimidazole, adamantyl, naphthyl,
2 phenyl, pyrrole, quinolinyl, or cycloalkyl rings to any extent.

3 Benzimidazole Ketones include, but are not limited to:

- 4 a. naphthalen-1-yl(1-pentyl-1H-benzo[d]imidazol-2-
5 1)methanone (JWH-018 benzimidazole analog), or
- 6 b. (1-(5-fluoropentyl)-1H-benzo[d]imidazol-2-
7 yl)(naphthalen-1-yl)methanone (FUBIMINA); and

8 14. Modified by Replacement: any compound defined in this
9 subsection that is modified by replacement of a carbon with nitrogen
10 in the indole, naphthyl, indene, benzimidazole, or carbazole ring.

11 H. Any material, compound, mixture, extract, or preparation
12 that contains a prohibited kratom product as provided in paragraphs
13 3 and 4 of subsection A of Section 1-1432.4 of this title.

14 I. Any prescription drug approved by the federal Food and Drug
15 Administration under the provisions of Section 505 of the Federal
16 Food, Drug, and Cosmetic Act, Title 21 of the United States Code,
17 Section 355, that is designated, rescheduled, or deleted as a
18 controlled substance under federal law by the United States Drug
19 Enforcement Administration shall be excluded from Schedule I and
20 shall be prescribed, distributed, dispensed, or used in accordance
21 with federal law upon the issuance of a notice, final rule, or
22 interim final rule by the United States Drug Enforcement
23 Administration designating, rescheduling, or deleting as a
24 controlled substance such a drug product under federal law, unless

1 and until the State Board of Pharmacy takes action pursuant to
2 Section 2-201 of this title. If the Board of Pharmacy does not take
3 action pursuant to Section 2-201 of this title, the drug product
4 shall be deemed to be designated, rescheduled, or deleted as a
5 controlled substance in accordance with federal law and in
6 compliance with the Uniform Controlled Dangerous Substances Act.

7 SECTION 2. This act shall become effective November 1, 2025.

8 Passed the Senate the 25th day of March, 2025.

9
10 _____
11 Presiding Officer of the Senate

12 Passed the House of Representatives the ____ day of _____,
13 2025.

14
15 _____
16 Presiding Officer of the House
17 of Representatives
18
19
20
21
22
23
24